Literature DB >> 24356243

Cannabis finds its way into treatment of Crohn's disease.

Rudolf Schicho1, Martin Storr.   

Abstract

In ancient medicine, cannabis has been widely used to cure disturbances and inflammation of the bowel. A recent clinical study now shows that the medicinal plant Cannabis sativa has lived up to expectations and proved to be highly efficient in cases of inflammatory bowel diseases. In a prospective placebo-controlled study, it has been shown what has been largely anticipated from anecdotal reports, i.e. that cannabis produces significant clinical benefits in patients with Crohn's disease. The mechanisms involved are not yet clear but most likely include peripheral actions on cannabinoid receptors 1 and 2, and may also include central actions.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24356243      PMCID: PMC4076530          DOI: 10.1159/000356512

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  10 in total

1.  Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing.

Authors:  Karen Wright; Nicholas Rooney; Mark Feeney; Jeremy Tate; Duncan Robertson; Melanie Welham; Stephen Ward
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

2.  Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.

Authors:  Nina L Cluny; Catherine M Keenan; Marnie Duncan; Alyson Fox; Beat Lutz; Keith A Sharkey
Journal:  J Pharmacol Exp Ther       Date:  2010-06-22       Impact factor: 4.030

3.  Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis.

Authors:  Udai P Singh; Narendra P Singh; Balwan Singh; Robert L Price; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Toxicol Appl Pharmacol       Date:  2011-11-18       Impact factor: 4.219

4.  Treatment of Crohn's disease with cannabis: an observational study.

Authors:  Timna Naftali; Lihi Bar Lev; Doron Yablecovitch; Doron Yablekovitz; Elisabeth Half; Fred M Konikoff
Journal:  Isr Med Assoc J       Date:  2011-08       Impact factor: 0.892

Review 5.  Cannabinoids and the gut: new developments and emerging concepts.

Authors:  Angelo A Izzo; Keith A Sharkey
Journal:  Pharmacol Ther       Date:  2010-02-01       Impact factor: 12.310

6.  Cannabis use amongst patients with inflammatory bowel disease.

Authors:  Simon Lal; Neeraj Prasad; Manijeh Ryan; Sabrena Tangri; Mark S Silverberg; Allan Gordon; Hillary Steinhart
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-10       Impact factor: 2.566

7.  The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease.

Authors:  A Di Sabatino; N Battista; P Biancheri; C Rapino; L Rovedatti; G Astarita; A Vanoli; E Dainese; M Guerci; D Piomelli; S L F Pender; T T MacDonald; M Maccarrone; G R Corazza
Journal:  Mucosal Immunol       Date:  2011-04-06       Impact factor: 7.313

Review 8.  The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity.

Authors:  Mireille Alhouayek; Giulio G Muccioli
Journal:  Trends Mol Med       Date:  2012-08-21       Impact factor: 11.951

9.  Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study.

Authors:  Timna Naftali; Lihi Bar-Lev Schleider; Iris Dotan; Ephraim Philip Lansky; Fabiana Sklerovsky Benjaminov; Fred Meir Konikoff
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-04       Impact factor: 11.382

10.  Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue.

Authors:  Lucia Marquéz; Juan Suárez; Mar Iglesias; Francisco Javier Bermudez-Silva; Fernando Rodríguez de Fonseca; Montserrat Andreu
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

  10 in total
  13 in total

1.  Cannabis Smoking and Diabetes Mellitus: Results from Meta-analysis with Eight Independent Replication Samples.

Authors:  Omayma Alshaarawy; James C Anthony
Journal:  Epidemiology       Date:  2015-07       Impact factor: 4.822

2.  Therapeutic Use of Cannabis in Inflammatory Bowel Disease.

Authors:  Waseem Ahmed; Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-11

3.  Intestinal P-glycoprotein exports endocannabinoids to prevent inflammation and maintain homeostasis.

Authors:  Rose L Szabady; Christopher Louissaint; Anneke Lubben; Bailu Xie; Shaun Reeksting; Christine Tuohy; Zachary Demma; Sage E Foley; Christina S Faherty; Alejandro Llanos-Chea; Andrew J Olive; Randall J Mrsny; Beth A McCormick
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 14.808

4.  Acute inflammation: endogenous cannabinoids mellow the harsh proinflammatory environment.

Authors:  Andrew S Neish
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 14.808

5.  Cannabis for the treatment of ulcerative colitis.

Authors:  Tahir S Kafil; Tran M Nguyen; John K MacDonald; Nilesh Chande
Journal:  Cochrane Database Syst Rev       Date:  2018-11-08

Review 6.  Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

Authors:  Carina Hasenoehrl; Martin Storr; Rudolf Schicho
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2017-02-16       Impact factor: 3.869

7.  Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts.

Authors:  Rameshprabu Nallathambi; Moran Mazuz; Aurel Ion; Gopinath Selvaraj; Smadar Weininger; Marcelo Fridlender; Ahmad Nasser; Oded Sagee; Puja Kumari; Diana Nemichenizer; Maayan Mendelovitz; Nave Firstein; Orly Hanin; Fred Konikoff; Yoram Kapulnik; Timna Naftali; Hinanit Koltai
Journal:  Cannabis Cannabinoid Res       Date:  2017-07-01

8.  Experiences of Chinese patients with Crohn's disease in the self-administration of nasogastric feeding: A descriptive qualitative study.

Authors:  Qian Cai; Fang Li; Yunxian Zhou
Journal:  PLoS One       Date:  2018-07-30       Impact factor: 3.240

9.  Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians.

Authors:  Megan C Buckley; Anand Kumar; Arun Swaminath
Journal:  Adv Ther       Date:  2021-06-10       Impact factor: 3.845

Review 10.  DAG tales: the multiple faces of diacylglycerol--stereochemistry, metabolism, and signaling.

Authors:  Thomas Oliver Eichmann; Achim Lass
Journal:  Cell Mol Life Sci       Date:  2015-07-08       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.